Tranzactioneaza Oncopeptides Ab (SE.ONCO) - 2.125 SEK (%) Tranzactioneaza

1D
1W
1M
3M
6M
1Y
5Y
Max

Indici

Bid 2.0750 SEK
Ask 2.1450 SEK
Minim 2.1200 SEK
Maxim 2.1300 SEK
Pret referinta 2.1200
Volum -
Volum ultima zi 1
Max 52 sapt 8.3600 SEK
Min 52 sapt 1.9980 SEK

Descriere companie

Oncopeptides AB (www.oncopeptides.se) is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Informatii companie

Nume

Oncopeptides AB